Rimiterol Explained

Rimiterol (INN/USAN) is a third-generation[1] short-acting[2] [3] β2 agonist.

See also

Notes and References

  1. Palma-Carlos AG, Palma-Carlos GS . Beta-2-agonists of third generation . Allergie et Immunologie . 18 . 4 . 31–2, 35 . April 1986 . 2899434 .
  2. Lai CK, Twentyman OP, Holgate ST . The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness . The American Review of Respiratory Disease . 140 . 4 . 917–23 . October 1989 . 2572192 . 10.1164/ajrccm/140.4.917 .
  3. Ydreborg SO, Svedmyr N, Thiringer G . Comparison of rimiterol and terbutaline, given by aerosol, in a long-term study . Scandinavian Journal of Respiratory Diseases . 58 . 2 . 117–24 . April 1977 . 16339 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rimiterol".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.